Cel Sci Corporation (CVM)

[Biobonic]

Re thinking the value of Multikine

Been slow on the uptake...

Outline: The vision of Geert Kirsten

A.) Vision
Develop a product that helps the body's immune system destroy cancerous tumors. Decade later the product has been developed.

B.) Vehicle:
Find a cancer that is tumorous, orphan designated, little studied. A cancer that Cel Sci can use to demonstrate the benefits of Mutlikine without stepping on the toes of other health companies.

Multikine is being tested on head and neck cancer.

C.) Value

A successful Phase 3 clinical trial will demonstrate the value of Multikine in immunotherapy against most every tumorous cancer.

This is NOT just a head and neck immunotherapy drug, it is a tumorous cancer drug.

60,000 head and neck cancers a year in the US.

Over 1.7 million people will be diagnosed with cancer this year in the US. (Not everyone of these would find benefit from Multikine)

But maybe 600,000 to a million might.


Thoughts are welcome.